Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose cancer has already received standard first-line treatment and has been confirmed as unable to be removed by surgery, has spread to other parts of the body, has continued to grow, or has come back.
• People whose tumor has been tested and shows positive expression of specific proteins called NG2 and DLL3, confirmed through laboratory testing of tumor tissue or cells.
• People who weigh at least 40 kg (approximately 88 pounds).
• People aged 18 to 75 years old at the time of joining the trial.
• People with a life expectancy of at least 8 weeks.
• People whose serious side effects from any previous cancer treatment have reduced to a mild-to-moderate level (grade 2 or lower).
• People who have not received blood cell growth-stimulating injections for at least 1 week before a specific cell collection procedure.
• People for whom at least 7 days have passed since completing certain targeted cancer therapies or low-dose chemotherapy regimens.
• People for whom at least 4 weeks have passed since receiving a monoclonal antibody treatment.
• People for whom at least 1 week has passed since any radiation therapy.
• People who are in a reasonably good general physical condition, as measured by a standard performance score of 70% or higher (confirm with trial site).
• People whose heart pumping function meets a minimum threshold, as measured by a specific heart scan (confirm with trial site).
• People whose blood oxygen level on room air is 90% or above.
• People whose liver function blood test results are within acceptable ranges as defined by the trial (confirm with trial site).
• People whose kidney function blood test results are within acceptable ranges as defined by the trial (confirm with trial site).
• People whose blood cell counts meet minimum levels, including white blood cells, infection-fighting cells, immune cells, and platelets — where the platelet count has not been achieved through a transfusion.
• People with cancer that has spread to the bone marrow may still be considered, provided their blood count results meet the required levels.
• People for whom a parent or legal guardian has signed the required consent and agreement forms on their behalf.

Who may not be able to join:

• People with serious existing illness affecting major organs such as the heart, lungs, or liver, or with significant loss of function in a major organ (except for certain blood-related side effects at a specific grade level).
• People with untreated cancer that has spread to the brain or spinal cord — though people whose brain or spinal cord involvement has been treated and has been stable for at least 6 weeks may still be considered.
• People who have previously received a different type of genetically engineered CAR T cell therapy.
• People with an active HIV, Hepatitis B, or Hepatitis C infection, or any other infection that is not currently under control.
• People who require ongoing steroid medication or other treatments that suppress the immune system.
• People whose tumor appears to be at risk of blocking the airway.
• People who would not be able to follow the requirements of the trial.
• People for whom an insufficient number of the specialised CAR T cells can be produced for treatment.

Important: Always verify eligibility with the trial site directly before applying.